In active ulcerative colitis, risankizumab induced and maintained remission.
rct · Level II
Where this comes from
- Record sourced from PubMed, PMID 39496179.
- Also identified by DOI 10.7326/ANNALS-24-02768-JC.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Louis E, Schreiber S, Panaccione R, et al; INSPIRE and COMMAND Study Group. <b>Risankizumab for ulcerative colitis: two randomized clinical trials.</b> JAMA. 2024;332:881-897. 39037800.
Medical subject headings
- Colitis, Ulcerative
- Antibodies, Monoclonal